背景:我们以前记录了米糠油(RBO)对男性冠状动脉疾病患者心功能和致动脉粥样硬化心脏代谢因子的有益作用。因此,该领域的现有证据旨在通过调查在日常标准饮食中添加RBO对新出现的胰岛素抵抗替代标志物的影响来扩展。脂质过氧化,抗氧化状态,和代谢综合征个体的代谢紊乱(MetSyn)通过开放标签对照试验。
方法:将50名超重/肥胖的成年人(平均体重指数(BMI)=31.08kg/m2)随机分配到对照组中,接受了标准的饮食计划,或干预组,补充30g/dRBO,持续8周。BMI,MetSyn组件,胰岛素抵抗代谢评分(METS-IR),甘油三酯葡萄糖BMI(TyGBMI),丙二醛(MDA),总抗氧化能力(TAC),在这个开放标签试验之前和之后测量血浆多酚水平。
结果:对基线值进行校正的协方差分析(ANCOVA)显示,与仅接受标准饮食的患者相比,补充30g/dRBO的人总胆固醇显着降低(P值=0.005;效应大小(ES):-0.92),LDL-胆固醇(P值=0.048;ES:-0.62),空腹血糖(P值=0.014;ES:-0.77),MDA(P值=0.002;ES:-1.01),METS-IR(P值<0.001;ES:-1.24),8周后,TyG-BMI(P值=0.007;ES:-0.85)。此外,RBO消耗导致显著更高水平的HDL-C(P值=0.004;ES:0.94)和TAC(P值<0.0001;ES:2.05)。然而,BMI没有显著变化,腰围,血清甘油三酯,血浆多酚,或血压。
结论:尽管目前的研究结果表明低胆固醇血症,抗高血糖,30g/dRBO的抗氧化作用似乎对MetSyn患者很有希望,他们应该被认为是初步的。因此,需要进一步设计良好的临床试验和更大的样本量和更长的持续时间来证实这些发现.
BACKGROUND: We previously documented the beneficial effects of rice bran oil (RBO) on cardiac function and atherogenic cardiometabolic factors in men with coronary artery disease. Therefore, the existing evidence in this area aims to be expanded by investigating the impact of adding RBO to a daily standard diet on emerging insulin resistance surrogate markers, lipid peroxidation, antioxidant status, and metabolic disturbances in individuals with metabolic syndrome (MetSyn) through an open-label controlled trial.
METHODS: A total of 50 overweight/obese adults (mean body mass index (BMI) = 31.08 kg/m2) with at least 3 MetSyn components were randomly allocated to either the control group, which received a standard diet plan, or the intervention group, which was supplemented with 30 g/d RBO for 8 weeks. BMI, MetSyn components, metabolic score for insulin resistance (METS-IR), triglyceride‒glucose‒BMI (TyG‒BMI), malondialdehyde (MDA), total antioxidant capacity (TAC), and plasma polyphenol levels were measured before and after this open-label trial.
RESULTS: Analysis of covariance (ANCOVA) adjusted for baseline values revealed that, compared with patients who received only a standard diet, those who were supplemented with 30 g/d RBO presented significantly lower total cholesterol (P value = 0.005; effect size (ES):-0.92), LDL-cholesterol (P value = 0.048; ES:-0.62), fasting blood glucose (P value = 0.014; ES:-0.77), MDA (P value = 0.002; ES: -1.01), METS-IR (P value < 0.001; ES: -1.24), and TyG-BMI (P value = 0.007; ES:-0.85) after 8 weeks. Additionally, RBO consumption resulted in significantly higher levels of HDL-C (P value = 0.004; ES:0.94) and TAC (P value < 0.0001; ES:2.05). However, no significant changes were noted in BMI, waist circumference, serum triglycerides, plasma polyphenols, or blood pressure.
CONCLUSIONS: Although the current findings suggest that the hypocholesterolemic, antihyperglycemic, and antioxidative effects of 30 g/d RBO seem to be promising for MetSyn patients, they should be considered preliminary. Therefore, further well-designed clinical trials with larger sample sizes and longer durations are needed to confirm these findings.